Monographie - Tigecycline

Последно актуализиране :
19/11/2024

Tigecycline

Химична структура

Търговско наименование

Търговските имена са примерни и съставът на помощните вещества може да бъде различен в зависимост от държавата и лабораториите

Eticina	Мексико
Grexyl	Мексико
Linicetil	Мексико
Mrsacin	Турция
Tecygen	Чили
Tigecid	Турция
Tigecilina	Аржентина, Еквадор, Чили
Tigecycline	Канада
Tigetop	Чили
Tizoxim	Аржентина
Tygacil	Австрия, Аржентина, Белгия, Великобритания, Венецуела, Германия, Гърция, Дания, Еквадор, Ирландия, Исландия, Испания, Италия, Канада, Колумбия, Люксенбург, Малайзия, Мексико, нова Зеландия, Норвегия, Обединени арабски емирства, Перу, Полша, Португалия, Румъния, Саудитска Арабия, Съединени Американски щати / САЩ, Турция, Унгария, Финландия, Франция, Холандия, Чили, Швейцария, Швеция, Япония
Zomiprerin	Перу

Библиография : Tigecycline

	Вид	Публикация
2262	Списание	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Лаборатория	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	Списание	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Лаборатория	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Лаборатория	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Лаборатория	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Лаборатория	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	Плакат	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Плакат	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Плакат	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	Списание	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	Списание	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Списание	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	Списание	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Списание	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales